Skip to main content
. 2023 May 8;8(9):e167664. doi: 10.1172/jci.insight.167664

Figure 1. RV306 and RV328 study design.

Figure 1

(A) Each RV306 participant received ALVAC-HIV and AIDSVAX B/E either alone or in combination at the indicated time points. RV328 participants received AIDSVAX B/E alone at the indicated time points. Comparative analysis was performed on week 50 for RV306 and week 26 for RV328, coinciding with 3 AIDSVAX B/E protein administrations within each study. Univariate analysis of TH023-specific CD4+ T cells expressing IFN-γ (B), IL-2 (C), and TNF-α (D). COMPASS revealed significantly higher functionality (E) and polyfunctionality (F) scores as well as increased proliferation (G) in CD4+ TH023 T cell responses in participants who received ALVAC-HIV. The dotted red line in G indicates the cutoff for positivity. For functionality and polyfunctionality scores, n = 33 for participants receiving ALVAC-HIV and AIDSVAX B/E and n = 30 for those who received AIDSVAX B/E alone. For CD4+ T cell proliferation, n = 34 for participants receiving ALVAC-HIV and AIDSVAX B/E and n = 26 for those who received AIDSVAX B/E alone. Data are presented as the median and IQR. Statistical significance was assessed using the Mann-Whitney U test.